PRESS RELEASES

FDA grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma, February 22, 2012 [Hebrew version]
OphthaliX announces issuance of Chinese Patent for the treatment of Dry Eye Disorders, February 22, 2012 [Hebrew version]
OphthaliX announces the appointment of Prof. Roger Kornberg as a Director. February 6, 2012 [Hebrew version]
Can-Fite BioPharma announces successful results of its Phase I/II Liver Cancer study with its CF102 Drug; the Study achieved the primary and secondary endpoints. January 3, 2012. [Hebrew version]
OphthaliX Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study, December 21, 2012 [Hebrew version]
Can-Fite is spinning off its ophthalmic indications to a US based public company in a $50 million valuation. November 22, 2011. [Hebrew version]
Can-Fite Announces the Initiation of Patient Enrolment for the Phase 2/3 Psoriasis Study with its Lead Drug CF101. August 1, 2011. [Hebrew version]
Can-Fite Signed an Agreement to Spin off its Ophthalmology Activities to a US Based Public Company. June 5, 2011. [Hebrew version]
Can-Fite announces a promising interim analysis data of its Phase I/II Liver Cancer study with the CF102 Drug. May 11, 2011. [Hebrew version]
Can-Fite announces the initiation of phase 3 in Dry Eye Syndrome. September 6, 2010. [Hebrew version]
Can-Fite drug candidate CF102 significantly decreased viral load of HCV in 3 Patients with Liver Cancer. July 25, 2010. [Hebrew version]
Can-Fite’s drug CF102 significantly decreased viral load of HCV in a Patient with Liver Cancer. May 30, 2010. [Hebrew version]
Can Fite BioPharma Receives Israeli MoH Approval to Conduct a Phase II Clinical Trial Evaluating the Efficacy of CF101 in Patients with Glaucoma. May 23, 2010. [Hebrew version]
Can Fite steps forward to the 3rd and last stage of its Phase I/II Liver Cancer study with the CF102 Drug. March 31, 2010. [Hebrew version]
Morningside and Can Fite BioPharma to Establish a Joint Venture to Develop and Commercialize Can-Fite’s CF102 Drug for the Treatment of Liver Diseases. Januay 19, 2010. [Hebrew version]
Can-Fite BioPharma to Initiate Phase II Clinical Trial with CF101 for the Treatment of Glaucoma. December 13, 2009. [Hebrew version]
Following the successful completion of two phase II clinical trials, Can Fite BioPharma retains Plexus Ventures to Partner their Phase II Lead Compound, Developed for Psoriasis and Other Indications. November 24, 2009. [Hebrew version]
Can-Fite Initiates Preparatory Work for Psoriasis Phase III Trial with CF101. September 29, 2009. [Hebrew version]
Can-Fite Announces Positive Results from its Psoriasis Phase II Trial with CF101. September 7, 2009. [Hebrew version]
Can-Fite BioPharma Expands its Pipeline by Licensing Allosteric Modulators from Leiden University and the NIH. July 28, 2009. [Hebrew version]
Can-Fite BioPharma to Initiate Phase I/II Clinical Trial with CF102 for the Treatment of Hepatitis C Virus. About 180 milion people of the world’s population are infected with HCV; The HCV market cap is currently estimated to be US$ 3 billion. July 14, 2009. [Hebrew version]
Can-Fite Completed Patient Enrollment for the Phase II Trial in Psoriasis with CF101. The patients were treated with CF101 as a stand alone similarly to the patients in the successful Dry Eye study. The Psoriasis market cap is currently estimated to be US$ 3.5 billion. May 31, 2009. [Hebrew version]
Can-Fite Announces Positive Results from its Phase II Trial Treating Keratoconjunctivitis Sicca (Dry Eye Syndrome) with CF101. Dry Eye affects more than 20 million people in the US alone. May 17, 2009. [Hebrew version]
A Phase IIb Study Testing the Combination of Methotrexate and CF101 in Rheumatoid Arthritis Patients Failed to Achieve Primary Efficacy Endpoint. Can-Fite Continues to Develop CF101 as a Stand-alone Therapy for Other Clinical Indications. April 30, 2009. [Hebrew version]
Can-Fite BioPharma to Initiate Phase I/II Clinical Trial with CF102 for the Treatment of Liver Cancer. Liver cancer is one of the five most common types of cancer globally, accounting for about 450,000 new diagnoses each year. Can-Fite expects to release within weeks the results of a phase IIB trial with CF101 for the treatment of rheumatoid arthritis and Phase IIa trial for the treatment of Dry Eye Syndrome. April 16, 2009. [Hebrew version]
Can-Fite Completed Patient Enrollment for the Phase II Trial in Dry Eye Syndrome with CF101. Company estimates to release data on Q2 2009. The Dry Eye Syndrome market cap is currently estimated to be US$ 1 billion. January 28, 2009. [Hebrew version]
Can-Fite Completed Patient Enrollment for the Confirmatory Phase IIb Trial in Rheumatoid Arthritis Patients with CF101. Company estimates to release data on Q2 2009. The arthritis market cap is currently estimated to be US$ 11 billion. December 29, 2008. [Hebrew version]
Out License of Rights for CF101 in Korea to Kwang Dong Pharmaceutical Co. Ltd. Can-Fite Expects to Receive US$ 1.5 Million from Licensing Fees and Milestone Payments in addition to Substantial Royalties. Additionally, Kwang Dong will also purchase equity in Can-Fite in an amount representing approximately 1% of Can-Fite’s outstanding share capital at a premium of 50% above market priceS. December 22, 2008. [Hebrew version]
Can-Fite signs MOU with the Korean company Kwang Dong Pharmaceutical for licensing CF101 rights for Korea. September 9, 2008. [Hebrew version]
Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, is to Commence Phase I Clinical Trial in Japan with CF101 for the Treatment of Rheumatoid Arthritis. Can-Fite will receive USD 1 M upon clinical study initiation. August 17, 2008. [Hebrew version]
Can-Fite Successfully Completed Phase I Clinical Trial with its 2nd Drug CF102. Prepares for next phase of clinical trials in liver diseases. May 4, 2008. [Hebrew version]
Can-Fite: First Patient was enrolled to the Phase IIb Rheumatoid Arthritis Trial. The study will include 230 RA patients at 30 medical sites in Europe and Israel.Rheumatoid Arthritis market is currently estimated at about $11 billion. April 1, 2008. [Hebrew version]
Can-Fite Initiated Phase I Clinical Trial with CF102. First Cohort was Successfully Completed. CF102 is indicated for the treatment of liver diseases. February 17, 2008. [Hebrew version]
Can-Fite and NIH Signed a Continuation of M-CRADA to Further Investigate CF101 for the Treatment of Uveitis. The agreement was signed based on positive data generated at leading lab at the National Eye Institute (NEI) at the NIH. A successful collaboration will prompt Can-Fite to the conductance of a Phase II clinical trial to test the efficacy of CF101 in the treatment of Uveitis. Uveitis is an inflammatory disease that involves the internal parts of the eye; it affects about 1 million people worldwide and its current market is estimated at about half a billion dollars. January 16, 2008. [Hebrew version]
Can-Fite Receives FDA Approval to Conduct Phase I Study with CF102. IND application submitted by Can-Fite last month was approved; phase I study will be initiated in the US in Q1 2008. The Company also received $0.5 million minimal royalty payment on CF101 from Seikagaku Corporation (SKK). January 7, 2008. [Hebrew version]
Can-Fite to Collaborate with Leading Academic Institutes in the Development of CF102. Under this collaboration the effect of CF102 on HCV replication in hepatocytes and molecular mechanisms involved with the antiviral activity of CF102 will be explored. Agreements were signed with world leading laboratories in the field of virology at the Israel's Rabin Medical Center and Temple University in Philadelphia. December 302, 2007. [Hebrew version]
Can-Fite: IND submission for Phase I Clinical Trials with its Drug for Liver Diseases CF102. Can-Fite develops CF102 for the treatment of liver cancer, hepatitis virus infections and other liver conditions that represent a current market of about USD 4 billion. Can-Fite estimates that this Phase I study will be initiated in early 2008, subject to FDA approval. December 2, 2007. [Hebrew version]
Can-Fite: CF101 may be Effective for the Treatment of Crohn's Disease. Market size in the US alone, with about 500,000 Crohn's patients is estimated at approximately USD 5 billion. Can-Fite will present these results at the annual meeting of the American College of Rheumatology (ACR), held this week in Boston. November 6, 2007. [Hebrew version]
Can-Fite to Conduct a Confirmatory Phase IIb Trial in Early 2008 as Part of Ongoing Development of CF101 for the Treatment of Rheumatoid Arthritis. Can-Fite's Clinical Advisory Board has recommended this advanced trial as further evidence for the efficacy observed in a previous trial; this will give green light to the final phase of development. October 23, 2007. [Hebrew version]
Can-Fite: CF102 Drug is Effective in Promoting Liver Tissue Regeneration; Clinical Trials with CF102 in the Treatment of Liver Cancer are Due to Commence in Early 2008. Can-Fite filed a patent on the use of the drug to promote liver tissue regeneration; this is in addition to the original indication in the treatment of liver cancer and viral hepatitis. October 21, 2007. [Hebrew version]
Can-Fite Achieved Additional Milestone Payment within the Framework of its Agreement with Seikagaku Corporation (SKK): To Receive $500,000. The total sum paid by SKK to Can-Fite to date amounts to $5 million. Can-Fite and SKK are jointly pursuing several non-clinical studies in the US aimed at supporting CF101 drug development. October 16, 2007. [Hebrew version]
Can-Fite Develops a Blood Test to Predict Patients’ Response to the Company Drugs. The test measures blood levels of the A3 adenosine receptor, the target attacked by Can-Fite's drugs; the test will predict patient’s response to treatment. The Company has applied for a patent to protect this technology. September 24, 2007. [Hebrew version]
Can-Fite Successfully Completes Preclinical Trials with its second Drug Candidate CF102. Soon to submit to the FDA an application for a phase I clinical trial. August 19, 2007. [Hebrew version]
Can-Fite: Pre-clinical Studies demonstrate that the Excipients used in the Placebo and CF101 Drug Enhanced the Anti-inflammatory Effect of Methotrexate (MTX). July 24, 2007. [Hebrew version]
Can-Fite Reports Results of a Phase IIb Clinical Study in Rheumatoid Arthritis with CF101, an A3 Adenosine Receptor Agonist. The Results Support Further Clinical Development of CF101. July 15, 2007. [Hebrew version]
Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 will be Presented at the Annual European Congress of Rheumatology. June 13, 2007. [Hebrew version]
Can-Fite Successfully Completes Long-Term Toxicology Studies with CF101 in full GLP compliance with US FDA. June 3, 2007. [Hebrew version]
Can-Fite to Commence Phase II Clinical Trials to Investigate the Efficacy of CF101 in the Treatment of Psoriasis. The market for psoriasis therapies is estimated at about USD 3 billion. The Company has also completed the clinical portion of a phase IIb clinical trial for the treatment of rheumatoid arthritis, the results of which are expected to be released this summer. May 16, 2007. [Hebrew version]
Can-Fite Completes NIS 40 Million Private Placement of Shares and Options Within One Day. Due to over-subscription during the rapid issuance, the Company resolved to increase the capital-raising round by 19% more than originally planned . March 7, 2007. [Hebrew version]
Breakthrough for Can-Fite: CF102 Found to be Active against Hepatitis B Virus in Pre-Clinical Studies. Company signs collaboration agreement with leading laboratory at Philadelphia's Temple University to test the drug's antiviral activity. February 18, 2007. [Hebrew version]
Can-Fite progresses through clinical trials: completed enrolment of 250 patients in phase IIb rheumatoid arthritis (RA) trial. Can-Fite will receive a consideration of US$ 500,000 from Japanese Seikagaku Corporation for achieving another milestone under the joint agreement, and a further US$ 500,000 in royalties. January 14, 2007. [Hebrew version]
Can-Fite granted US patent on CF101 for Rheumatoid Arthritis (RA). The patent confers exclusive right to CF101 in the treatment of RA until 2023 December 19, 2006. [Hebrew version]
Can-Fite presents results showing a correlation between high expression of the receptor target for its drug CF101 and rheumatoid arthritis patients’ response to the drug. November 12, 2006. [Hebrew version]
Can-Fite progresses through clinical trials: completed enrolment of half the patients required for phase IIb RA trial and is scheduled to receive next payment from the Japanese Seikagaku Corporation. October 23, 2006. [Hebrew version]
Can-Fite to Develop CF102 for the Treatment of Liver Cancer. Canfite is currently conducting all the IND-enabling work that will support the initiation of Phase I clinical trials in Liver Cancer patients towards the end of 2007 . October 8, 2006. [Hebrew version]
Can-Fite Expects to Receive Up to US$ 19.5 Million from a Japanese Company and Collect Substantial Royalties from the Grants of Licensing Rights to Develop and Market CF101 in Japan . September 25, 2006. [Hebrew version]
Can-Fite to Develop CF101 for Psoriasis, Among Other Indications.
The company will commence preparations for phase II clinical trial in psoriasis. September 10, 2006. [Hebrew version]
Can-Fite BioPharma Received Israeli MoH Approval to Conduct a Clinical Trial Evaluating the Efficacy of CF101 in Patients with Dry Eye Syndrome. September 05, 2006. [Hebrew version]
Can-Fite Fite Initiated Phase IIb Clinical Trials in Rheumatoid Arthritis Patients; has achieved milestones enabling it to convert issued debentures. The Company has received the final report summarizing the results of the Phase IIa clinical trial in Rheumatoid Arthritis patients, demostrating a decrease in disease parameters. July 18, 2006. [Hebrew version]
Can-Fite on its way to Initiate Clinical Trials with Second Drug – CF102. Company initiated non-clinical developmenty of the drug. Jun 25, 2006. [Hebrew version]
The drug CF101 is not metabolized in the liver and can be used as potential therapy for liver related conditions. Jun 14, 2006. [Hebrew version]
214 Times Oversubscribed. Can-Fite Biopharma Concluded a NIS 30 Million Fund-raising for Funding Clinical Studies and Ongoing R&D. May 16, 2006. [Hebrew version]
Can-Fite Signs an MOU for Out-licensing Rights of CF101 for Inflammatory Indications in Japan . April 3, 2006. [Hebrew version]
Can-Fite to Initiate Clinical Studies to Test Efficacy of CF101 in Treating Dry Eyes Syndrome. April 3, 2006. [Hebrew version]
Can-Fite Biopharma Files Two New Patent Applications Relating to Very Important Therapeutic Indications. March 13, 2006. [Hebrew version]
Can-Fite Biopharma Appointed Dr. Ilan Cohn as Vice Chairman of the Board . February 6, 2006. [Hebrew version]
New Clinical Data on the Effect of CF101 in Improving Dry Eye Symptoms. January 30, 2006. [Hebrew version]
Can-Fite BioPharma Signed a Cooperative Research and Development Agreement (CRADA) with the US National Institute of Health (NIH). January 24, 2006. [Hebrew version]
Can-Fite Submitted its Protocol for a Phase IIb Clinical Study of CF101 in Rheumatoid Arthritis Patients to the US Food and Drug Administration (FDA). The Multinational Phase IIb Clinical Study Scheduled to Begin in Q2 of 2006. January 22, 2006. [Hebrew version]
Can-Fite’s Share will be included in the Tel-Tech share index of the Tel-Aviv Stock Exchange. December 19, 2005. [Hebrew version]
The Shareholders of Can-Fite BioPharma will be Requested to Approve the Appointment of Dr. Itzhak Krinsky, Vice President in Teva Pharmaceutical Industries and Prof. Yechezkel Barenholz from the Hebrew University as External Directors in the Company. December 6, 2005. [Hebrew version]
Data Demonstrating Positive Activity of CF101 in Rheumatoid Arthritis Patients will be Presented in the Forthcoming Annual Scientific Meeting of the American College of Rheumatology. November 6, 2005. [Hebrew version]
Michael Weiss, the Chairman and CEO of Keryx Biopharmaceuticals, Joins as an Observer of the Board of Directors of Can-Fite. October 10, 2005. [Hebrew version]
Israeli Biopharmaceutical Company "Can-Fite BioPharma" to raise NIS 45 million on the Tel-Aviv Stock Exchange. Michael Weiss and Alex Rabinovitch granted options for their contribution in raising investment interests. September 26, 2005. [English HTML version] [Hebrew version]
Can-Fite Initiates Phase I Multi-Center Trial of CF101 in Combination with Chemotherapy for Various Solid Tumors at Harvard Medical School. Can-Fite’s first US clinical study is now open at Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital. June 30, 2004.
Can-Fite Announces Interim Results of Phase II Study of CF101 for the Treatment of Colorectal Cancer in a Late Breaking Abstract Presentation at AACR in Orlando. Preliminary results show that CF101 is safe and successful in stabilizing solid tumors. March 30, 2004.
Can-Fite BioPharma Reinforces Its U.S. Management Team with the Appointment of a U.S.-based Chief Business Officer, Ashleigh Palmer. February 11, 2004.
Can-Fite BioPharma Research Data Shows CF101 to be Effective in Restraining the Growth of Colon, Prostate and Other Cancerous Tumors.
Company Primes for 2004 clinical study in the US of CF101 in Combination with Chemotherapy. January 6, 2004.
Can-Fite BioPharma Commences Phase II Trial of CF101 for the Treatment of Active Rheumatoid Arthritis.
Enrollment open to candidates at six leading medical centers in Israel. July 23, 2003.
Can-Fite BioPharma Announces An Investment by New-York fund BPW Israel Ventures LLC and the Completion of a US$12 Million Financing Round.
Company now enrolling candidates for a Phase II Trial of CF101 in Colorectal Cancer. June 11, 2003.
Can-Fite BioPharma Completes Two Phase I Trialsof its lead anti-cancer and anti-inflammatory drug CF101.
Company to commence two Phase II Trials in Q2 2003. April 10, 2003.

Israeli Biopharmaceutical Start-Up, Can-Fite BioPharma, Raises $10 Million As Part Of Its Second Fund-Raising Round Giza Venture Capital Leads The Round. July 2, 2002.